IPHA

Innate Pharma

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 3

Sell signal 0

stock price surged significantly

consensus rating "Strong Buy"

Upward Gap

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About IPHA

Innate Pharma S.A.

A company that developing therapeutic antibodies designed to harness the immune system to treat cancer

Industry

Biological Technology

Established Date

09/23/1999

Listing Date

10/17/2019

Exchange

NASDAQ Stock Exchange

Full-time Employees

179

Fiscal Year Ends

12-31

Website

www.innate-pharma.com/fr

Security Type

Depository Receipts (Ordinary Shares)

Office address

117 Avenue de Luminy, 13009 Marseille, France

Business

Introduction

Founded on September 23, 1999, Innate Pharma S.A. is a biotechnology company dedicated to the discovery, development and commercialization of first-in-class therapeutic antibodies designed to harness the immune system for the treatment of tumor indications with serious unmet medical needs. The company has extensive experience in the research and development of immuno-oncology and is a pioneer in understanding natural killer cell or NK cell biology.

Company Financials

EPS

IPHA has released its 2022 Q2 earnings. EPS was reported at 0.09, versus the expected 0.00, beating expectations. The chart below visualizes how IPHA has performed over recent quarters, highlighting trends in earnings surprises.